Yanxia Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yanxia Zhang has a total of 170 co-authors. Here are the top co-authors by number of shared publications:
- Qian Yu
State and Local Joint Engineering Laboratory for Novel Functional Polymeric Materials, College of Chemistry, Chemical Engineering and Materials Science, Soochow University, Suzhou 215123, PR China
33 shared publications - Hong Chen
State and Local Joint Engineering Laboratory for Novel Functional Polymeric Materials, College of Chemistry, Chemical Engineering and Materials Science, Soochow University, Suzhou, China
17 shared publications Kunyan Lu
State and Local Joint Engineering Laboratory for Novel Functional Polymeric Materials, College of Chemistry, Chemical Engineering and Materials Science, Soochow University, Suzhou, 215123, P. R. China
13 shared publicationsYi Zou
Department of Cardiovascular Surgery of the First Affiliated Hospital & Institute for Cardiovascular Science, Soochow University, Suzhou, 215006, P. R. China; State and Local Joint Engineering Laboratory for Novel Functional Polymeric Materials, College of Chemistry, Chemical Engineering and Materials Science, Soochow University, Suzhou, 215123, P. R. China
11 shared publicationsDongxu Jia
State and Local Joint Engineering Laboratory for Novel Functional Polymeric Materials, College of Chemistry, Chemical Engineering and Materials Science
10 shared publicationsQian Yu
Soochow University(Soochow University,Suzhou University),Suzhou,China
9 shared publications
Latest Publications
- 28 July 2026
- Published by Elsevier in Journal of Materials Science & Technology
- Vol. 284, 52-60
Hyaluronidase-responsive dual-functional nanoplatform for sequential biofilm deconstruction and photothermal eradication
- 28 July 2026
- Published by Elsevier in Journal of Materials Science & Technology
- Vol. 284, 52-60
Hyaluronidase-responsive dual-functional nanoplatform for sequential biofilm deconstruction and photothermal eradication
- 9 July 2026
- Published by American Chemical Society (ACS) in Biomacromolecules
- Vol. 27 (8) , 5816-5827
A Dual-Functional Antibiofilm Nanoplatform Integrating Photothermal Bactericidal Activity with Ga3 + -Mediated Iron Metabolism Interference
Bacterial biofilms severely compromise antibiotic efficacy and accelerate drug resistance. Herein, a dual-functional nanoplatform (Ga-PDA NPs) was constructed through the coordination-driven assembly of gallium ions (Ga3+) and polydopamine (PDA) for synergistic photothermal and metabolic antibiofilm therapy. The PDA matrix serves as both a high-efficiency photothermal agent and a pH-responsive ligand, facilitating Ga3+ release within the acidic biofilm microenvironment. Under near-infrared irradiation, Ga-PDA NPs generate heat to disrupt bacterial membranes and the extracellular matrix. Concurrently, the released Ga3+ functions as a “Trojan horse,” penetrating bacterial cells to interfere with iron metabolism, thereby triggering lethal iron starvation and widespread metabolic dysfunction. In vitro experiments verified potent bactericidal activity against Pseudomonas aeruginosa and Staphylococcus aureus. Moreover, when incorporated into bacterial cellulose membranes, this composite system exhibited excellent biocompatibility and effectively promoted the healing of biofilm-infected wounds in mice. Overall, this dual-functional nanoplatform provides a promising therapeutic strategy for the management of biofilm-associated infections.
- 9 July 2026
- Published by American Chemical Society (ACS) in Biomacromolecules
- Vol. 27 (8) , 5816-5827
A Dual-Functional Antibiofilm Nanoplatform Integrating Photothermal Bactericidal Activity with Ga3 + -Mediated Iron Metabolism Interference
Bacterial biofilms severely compromise antibiotic efficacy and accelerate drug resistance. Herein, a dual-functional nanoplatform (Ga-PDA NPs) was constructed through the coordination-driven assembly of gallium ions (Ga3+) and polydopamine (PDA) for synergistic photothermal and metabolic antibiofilm therapy. The PDA matrix serves as both a high-efficiency photothermal agent and a pH-responsive ligand, facilitating Ga3+ release within the acidic biofilm microenvironment. Under near-infrared irradiation, Ga-PDA NPs generate heat to disrupt bacterial membranes and the extracellular matrix. Concurrently, the released Ga3+ functions as a “Trojan horse,” penetrating bacterial cells to interfere with iron metabolism, thereby triggering lethal iron starvation and widespread metabolic dysfunction. In vitro experiments verified potent bactericidal activity against Pseudomonas aeruginosa and Staphylococcus aureus. Moreover, when incorporated into bacterial cellulose membranes, this composite system exhibited excellent biocompatibility and effectively promoted the healing of biofilm-infected wounds in mice. Overall, this dual-functional nanoplatform provides a promising therapeutic strategy for the management of biofilm-associated infections.
- 19 March 2026
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 18 (12) , 17648-17659
An Antibiotic-Free Nanoplatform Synergizing Quorum Sensing Inhibition and Enhanced Chemodynamic Therapy
Biofilm-associated infections remain a major challenge, as the inherent recalcitrance of the extracellular polymeric substance matrix renders conventional antibiotics ineffective, further driving antimicrobial resistance. To address this, combination therapies have emerged as a potent strategy to enhance therapeutic outcomes. In this study, a dual-functional, antibiotic-free nanoplatform was designed to eradicate biofilms through combined quorum sensing (QS) inhibition and chemodynamic therapy (CDT). This nanoplatform consists of calcium peroxide (CaO2) nanoparticles coated with a quercetin/copper ion (Qe/Cu2+) complex. Upon exposure to the acidic biofilm microenvironment, the Qe/Cu2+ complex dissociates, releasing Qe and Cu2+ while exposing the CaO2 core. The subsequent reaction of CaO2 with water generates hydrogen peroxide, which is then catalyzed by Cu2+ via a Fenton-like reaction to produce highly bactericidal hydroxyl radicals. Simultaneously, Qe disrupts bacterial QS pathways, attenuating pathogenicity and sensitizing the biofilm-embedded bacteria to oxidative damage. This antibiotic-free nanoplatform demonstrated robust in vitro antibiofilm activity against Pseudomonas aeruginosa and Staphylococcus aureus, while significantly reducing bacterial colonization and accelerating wound healing in an infected mouse model, suggesting that the synergetic integration of QS inhibition and CDT represents a promising strategy for combating biofilm-associated infections.
- 19 March 2026
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 18 (12) , 17648-17659
An Antibiotic-Free Nanoplatform Synergizing Quorum Sensing Inhibition and Enhanced Chemodynamic Therapy
Biofilm-associated infections remain a major challenge, as the inherent recalcitrance of the extracellular polymeric substance matrix renders conventional antibiotics ineffective, further driving antimicrobial resistance. To address this, combination therapies have emerged as a potent strategy to enhance therapeutic outcomes. In this study, a dual-functional, antibiotic-free nanoplatform was designed to eradicate biofilms through combined quorum sensing (QS) inhibition and chemodynamic therapy (CDT). This nanoplatform consists of calcium peroxide (CaO2) nanoparticles coated with a quercetin/copper ion (Qe/Cu2+) complex. Upon exposure to the acidic biofilm microenvironment, the Qe/Cu2+ complex dissociates, releasing Qe and Cu2+ while exposing the CaO2 core. The subsequent reaction of CaO2 with water generates hydrogen peroxide, which is then catalyzed by Cu2+ via a Fenton-like reaction to produce highly bactericidal hydroxyl radicals. Simultaneously, Qe disrupts bacterial QS pathways, attenuating pathogenicity and sensitizing the biofilm-embedded bacteria to oxidative damage. This antibiotic-free nanoplatform demonstrated robust in vitro antibiofilm activity against Pseudomonas aeruginosa and Staphylococcus aureus, while significantly reducing bacterial colonization and accelerating wound healing in an infected mouse model, suggesting that the synergetic integration of QS inhibition and CDT represents a promising strategy for combating biofilm-associated infections.
- 26 February 2026
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 18 (9) , 13585-13598
A β-Glycine-Enhanced Poly( l -lactic acid) Biopiezoelectric Patch for Self-Powered Myocardial Infarction Therapy
Cardiac patches, as implantable materials that provide mechanical stabilization and functional support to the heart, have shown promising therapeutic potential for the treatment of myocardial infarction (MI). However, promoting the electrical integration of cardiomyocytes is also crucial for MI treatment, and the related challenges have limited the application of cardiac patch materials lacking electromechanical functionality. Therefore, in this study, we developed a biocompatible, safely degradable, self-powered piezoelectric cardiac patch composed of poly(l-lactic acid) (PLLA) and β-glycine crystals via high-speed electrospinning. The optimized patch (PLLA-Gly-H) exhibited a high piezoelectric coefficient (d33 = 32.4 ± 1.6 pC·N–1) and sensitivity (21.24 ± 0.81 mV·kPa–1). In vitro, the patch was proven to have good biocompatibility (L929 cell survival ratio exceeded 99%) and enhanced human umbilical vein endothelial cell (HUVEC) spreading under piezoelectric stimulation (surface HUVEC coverage reached ∼88.5%). In vivo, when implanted in a murine MI model, PLLA-Gly-H significantly improved cardiac function (left ventricular ejection fractions: 47.7% vs 35.0% in the MI group), reduced fibrosis (41.5% reduction compared with that in the MI group), and promoted angiogenesis (vascular density reaching 4.387 ± 0.167 vessels·mm–2) and connexin-43 expression (1.389 ± 0.183% vs 0.639 ± 0.194% in the MI group). Overall, this work provides a conceptual advance for self-powered, biodegradable patch-mediated therapy for myocardial infarction.
- 26 February 2026
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 18 (9) , 13585-13598
A β-Glycine-Enhanced Poly( l -lactic acid) Biopiezoelectric Patch for Self-Powered Myocardial Infarction Therapy
Cardiac patches, as implantable materials that provide mechanical stabilization and functional support to the heart, have shown promising therapeutic potential for the treatment of myocardial infarction (MI). However, promoting the electrical integration of cardiomyocytes is also crucial for MI treatment, and the related challenges have limited the application of cardiac patch materials lacking electromechanical functionality. Therefore, in this study, we developed a biocompatible, safely degradable, self-powered piezoelectric cardiac patch composed of poly(l-lactic acid) (PLLA) and β-glycine crystals via high-speed electrospinning. The optimized patch (PLLA-Gly-H) exhibited a high piezoelectric coefficient (d33 = 32.4 ± 1.6 pC·N–1) and sensitivity (21.24 ± 0.81 mV·kPa–1). In vitro, the patch was proven to have good biocompatibility (L929 cell survival ratio exceeded 99%) and enhanced human umbilical vein endothelial cell (HUVEC) spreading under piezoelectric stimulation (surface HUVEC coverage reached ∼88.5%). In vivo, when implanted in a murine MI model, PLLA-Gly-H significantly improved cardiac function (left ventricular ejection fractions: 47.7% vs 35.0% in the MI group), reduced fibrosis (41.5% reduction compared with that in the MI group), and promoted angiogenesis (vascular density reaching 4.387 ± 0.167 vessels·mm–2) and connexin-43 expression (1.389 ± 0.183% vs 0.639 ± 0.194% in the MI group). Overall, this work provides a conceptual advance for self-powered, biodegradable patch-mediated therapy for myocardial infarction.
- Open Access
- 28 January 2026
- Published by Elsevier in Materials Today Bio
- Vol. 37, 102854
Injectable alginate composite hydrogel with spatiotemporal codelivery of pro-angiogenic and anti-fibrotic agents for synergistic myocardial repair
- 28 January 2026
- Published by Elsevier in Materials Today Bio
- Vol. 37, 102854
Open AccessInjectable alginate composite hydrogel with spatiotemporal codelivery of pro-angiogenic and anti-fibrotic agents for synergistic myocardial repair
- Top Cited Papers
- 14 January 2026
- Published by American Chemical Society (ACS) in Biomacromolecules
- Vol. 27 (2) , 1558-1568
A Natural Biomolecule-Based Coating with Antifouling and Quorum-Sensing Inhibition Properties for Preventing Biofilm Formation
Biofilm-associated infections present a critical healthcare challenge due to antibiotic resistance and frequent medical implant colonization. Preemptive surface coatings with antibiofilm properties are thus critical, yet conventional antifouling coatings only delay initial bacterial adhesion and poorly inhibit long-term biofilm formation. This study develops a versatile all-natural coating, combining phase-transited bovine serum albumin (PTB) as a structural matrix and a natural quorum-sensing inhibitor quercetin (Qe). The PTB framework delivers three core functions: stable adhesion to diverse substrates, immediate antifouling effects via reduced nonspecific protein/bacterial attachment, and sustained Qe release. Released Qe disrupts bacterial communication to inhibit biofilm maturation without bactericidal effects. Targeting both initial adhesion and maturation, this dual-action coating achieves broad-spectrum, prolonged antibiofilm activity against clinically significant pathogens, including Pseudomonas aeruginosa and Staphylococcus aureus. Its all-natural components ensure excellent cytocompatibility, rendering this facilely fabricated coating a safe, promising solution for biomedical antibiofilm applications.
- 14 January 2026
- Published by American Chemical Society (ACS) in Biomacromolecules
- Vol. 27 (2) , 1558-1568
Top Cited PapersA Natural Biomolecule-Based Coating with Antifouling and Quorum-Sensing Inhibition Properties for Preventing Biofilm Formation
Biofilm-associated infections present a critical healthcare challenge due to antibiotic resistance and frequent medical implant colonization. Preemptive surface coatings with antibiofilm properties are thus critical, yet conventional antifouling coatings only delay initial bacterial adhesion and poorly inhibit long-term biofilm formation. This study develops a versatile all-natural coating, combining phase-transited bovine serum albumin (PTB) as a structural matrix and a natural quorum-sensing inhibitor quercetin (Qe). The PTB framework delivers three core functions: stable adhesion to diverse substrates, immediate antifouling effects via reduced nonspecific protein/bacterial attachment, and sustained Qe release. Released Qe disrupts bacterial communication to inhibit biofilm maturation without bactericidal effects. Targeting both initial adhesion and maturation, this dual-action coating achieves broad-spectrum, prolonged antibiofilm activity against clinically significant pathogens, including Pseudomonas aeruginosa and Staphylococcus aureus. Its all-natural components ensure excellent cytocompatibility, rendering this facilely fabricated coating a safe, promising solution for biomedical antibiofilm applications.
- 7 August 2025
- Published by Elsevier in Journal of Colloid and Interface Science
- Vol. 701, 138628
A trifunctional coating for biofilm prevention: integrating antifouling, photothermal killing, and quorum sensing interference
- 7 August 2025
- Published by Elsevier in Journal of Colloid and Interface Science
- Vol. 701, 138628
A trifunctional coating for biofilm prevention: integrating antifouling, photothermal killing, and quorum sensing interference
- 7 August 2025
- Published by Elsevier in Colloids and Surfaces B: Biointerfaces
- Vol. 256 (Pt 2) , 115019
Engineered nanoplatform with DNase-mimetic catalysis and photothermal ablation for synergistic biofilm eradication
- 7 August 2025
- Published by Elsevier in Colloids and Surfaces B: Biointerfaces
- Vol. 256 (Pt 2) , 115019
Engineered nanoplatform with DNase-mimetic catalysis and photothermal ablation for synergistic biofilm eradication
- Top Cited Papers
- 15 July 2025
- Published by Elsevier in Acta Biomaterialia
- Vol. 203, 155-180
Multifunctional antibiofilm materials: surface engineering and nanotherapeutic strategies for biofilm prevention and eradication
- 15 July 2025
- Published by Elsevier in Acta Biomaterialia
- Vol. 203, 155-180
Top Cited PapersMultifunctional antibiofilm materials: surface engineering and nanotherapeutic strategies for biofilm prevention and eradication
- Open Access
- 14 December 2024
- Published by Oxford University Press (OUP) in Regenerative Biomaterials
- Vol. 12, rbae145
Neutrophil-derived apoptotic body membranes-fused exosomes targeting treatment for myocardial infarction
Myocardial infarction (MI) poses a substantial threat to human health, prompting extensive research into effective treatment modalities. Preclinical studies have demonstrated the therapeutic potential of mesenchymal stem cell-derived exosomes for cardiac repair. Despite their promise, the inherent limitations of natural exosomes, mainly their restricted targeting capabilities, present formidable barriers to clinical transformation. To address this, it is proposed to enhance their targeting specificity and retention in infarcted myocardium by fusing exosomes with neutrophil-derived apoptotic body membranes (NAM). These NAM inherit the surface signals from neutrophils, which allow them to home in on the damaged tissues and participate in regulating inflammatory responses. In this current work, we utilized a membrane fusion technique to create NAM-fused exosomes (NAM-Exo) for MI treatment. Compared to their native counterparts, NAM-Exo demonstrated enhanced adhesion to inflammatory endothelial cells, replicating the neutrophil recruitment mechanism at sites of myocardial injury in MI. Furthermore, our findings revealed that NAM-Exo not only significantly modulated inflammation responses but also promoted angiogenesis in a mouse model of MI, ultimately leading to improved cardiac function and ventricular remodeling post-treatment. These results underscore the potential of membrane fusion as an effective strategy to enhance the therapeutic efficacy of exosome-based cardiac repair and regeneration therapies, thereby paving the way for their translation into clinical practice.
- 14 December 2024
- Published by Oxford University Press (OUP) in Regenerative Biomaterials
- Vol. 12, rbae145
Open AccessNeutrophil-derived apoptotic body membranes-fused exosomes targeting treatment for myocardial infarction
Myocardial infarction (MI) poses a substantial threat to human health, prompting extensive research into effective treatment modalities. Preclinical studies have demonstrated the therapeutic potential of mesenchymal stem cell-derived exosomes for cardiac repair. Despite their promise, the inherent limitations of natural exosomes, mainly their restricted targeting capabilities, present formidable barriers to clinical transformation. To address this, it is proposed to enhance their targeting specificity and retention in infarcted myocardium by fusing exosomes with neutrophil-derived apoptotic body membranes (NAM). These NAM inherit the surface signals from neutrophils, which allow them to home in on the damaged tissues and participate in regulating inflammatory responses. In this current work, we utilized a membrane fusion technique to create NAM-fused exosomes (NAM-Exo) for MI treatment. Compared to their native counterparts, NAM-Exo demonstrated enhanced adhesion to inflammatory endothelial cells, replicating the neutrophil recruitment mechanism at sites of myocardial injury in MI. Furthermore, our findings revealed that NAM-Exo not only significantly modulated inflammation responses but also promoted angiogenesis in a mouse model of MI, ultimately leading to improved cardiac function and ventricular remodeling post-treatment. These results underscore the potential of membrane fusion as an effective strategy to enhance the therapeutic efficacy of exosome-based cardiac repair and regeneration therapies, thereby paving the way for their translation into clinical practice.